Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner

Date Published01/28/2022
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Oxford Biomedica
Parent companyOxford Biomedica Solutions LLC
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:20222
Domestically, the work will be done:In-house
Capital investment ($):130
Country(ies) from which reshored:United Kingdom
City reshored to:Near Boston
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredGene and cell therapy
Find Reshoring Articles